Periodic Reporting for period 1 - HapticCell (Haptic micromanipulation system for low cost autonomous microinjection tasks)
Reporting period: 2017-02-01 to 2018-01-31
The aim of the HapticCell project was to test the feasibility of creating a demonstrator that could perform autonomous microinjection tasks relevant to the IVF sector. Through visual-servoing, feature tracking and a control loop linked to a biomechanical cell model, we wanted to outline the design requirements needed for these technologies (initially developed through the main ERC-AdG grant) to work together and perform under operational market constraints. Further, we wanted to use the results from this project to define a commercial plan i.e. IPR position, freedom to operation (FTO) strategy etc. to then provide a foundation for technology adoption and commercialisation.
Through this ERC-PoC we achieved the following objectives:
1) Testing the technical feasibility of a control loop linked to a biomechanical model to support autonomous microinjection tasks
2) Customer workflow and SWOT analysis of current approaches and the use of automation
3) Implementation of the HaptiCell system for demonstrator to help attract future investment and support further work
4) Commercial planning, including patent searches and economic cost analysis
By working with the UCL Centre of Reproductive Genetic Health (CRGH), UCL Transgenic Services (TS), and UCL Business we identified a set of technical adaptions needed to improve the commercial feasibility of the HapticCell system. Further, we demonstrated key benefits of the HapticCell system in improving the working environment for embryologists, mechanical characterisation of oocytes via simulation and throughput in performing intracytoplasmic sperm (ICSI) injection tasks. Through end user testing, this led to a series of technical recommendations to then implement a second prototype. Future work includes successful implementation of identified recommendations related to the control loop and biomechanical model, in addition to patent protection of the updated system.
Through this ERC-PoC we achieved the following objectives:
1) Testing the technical feasibility of a control loop linked to a biomechanical model to support autonomous microinjection tasks
2) Customer workflow and SWOT analysis of current approaches and the use of automation
3) Implementation of the HaptiCell system for demonstrator to help attract future investment and support further work
4) Commercial planning, including patent searches and economic cost analysis
By working with the UCL Centre of Reproductive Genetic Health (CRGH), UCL Transgenic Services (TS), and UCL Business we identified a set of technical adaptions needed to improve the commercial feasibility of the HapticCell system. Further, we demonstrated key benefits of the HapticCell system in improving the working environment for embryologists, mechanical characterisation of oocytes via simulation and throughput in performing intracytoplasmic sperm (ICSI) injection tasks. Through end user testing, this led to a series of technical recommendations to then implement a second prototype. Future work includes successful implementation of identified recommendations related to the control loop and biomechanical model, in addition to patent protection of the updated system.